Physiologic role for enhanced renal thromboxane production in murine lupus nephritis.
To investigate the physiologic significance of enhanced renal thromboxane production in murine lupus nephritis, we measured renal hemodynamics and eicosanoid production in MRL-lpr/lpr mice from 8 to 20 weeks of age. Over this age range, MRL-lpr/lpr mice develop an autoimmune disease with nephritis similar to human systemic lupus erythematosus (SLE). In these studies, glomerular filtration rate (GFR) and PAH clearance (CPAH) decreased progressively with age in MRL-lpr/lpr mice, but not in controls. This impairment of renal hemodynamics was associated with increased renal thromboxane production, as well as increased excretion of both thromboxane B2 (TxB2) and 2,3-dinor TxB2 in urine. There was an inverse correlation between renal thromboxane production in MRL-lpr/lpr mice and both GFR and CPAH. Furthermore, there were positive correlations between thromboxane production by the kidney and both the severity of renal histopathology and serum anti-DNA antibody levels measured in individual animals. Enhanced urinary excretion of TxB2 and the development of renal dysfunction also coincided temporally with the appearance of increased levels of interleukin 1 beta (IL-1 beta) mRNA in renal cortex. Acute administration of the specific thromboxane receptor antagonist GR32191 to MRL-lpr/lpr mice restored GFR to normal in early stages of the autoimmune disease. However, in animals with more advanced nephritis, the effect of acute thromboxane receptor blockade on renal hemodynamics was less marked. We conclude that thromboxane A2 is an important mediator of reversible renal hemodynamic impairment in murine lupus, especially in the early phase of disease.
Spurney
R F
RF
Department of Medicine, Duke University, Durham, North Carolina 27705.
Bernstein
R J
RJ
Ruiz
P
P
Pisetsky
D S
DS
Coffman
T M
TM
D000367:Age Factors; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology; D015152:Blotting, Northern; D004247:DNA / Q000276:immunology; D006538:Heptanoic Acids / Q000494:pharmacology; D007375:Interleukin-1 / Q000235:genetics; D007668:Kidney / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D007677:Kidney Function Tests; D008181:Lupus Nephritis / Q000378:metabolism* / Q000503:physiopathology; D008657:Metabolic Clearance Rate / Q000502:physiology; D051379:Mice; D008815:Mice, Inbred Strains; D012333:RNA, Messenger / Q000032:analysis; D011863:Radioimmunoassay; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000097:blood*; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000378:metabolism
D001713:Biphenyl Compounds; D006538:Heptanoic Acids; D007375:Interleukin-1; D012333:RNA, Messenger; D013929:Thromboxane B2; D013928:Thromboxane A2; C028965:2,3-dinor-thromboxane B2; D004247:DNA; C060013:vapiprost